The CIO and portfolio manager of Arctic Aurora LifeScience, Ulrica Bjerke, visited EFN Stock Exchange this week. With the current turmoil and uncertainty in the world's financial markets, Ulrica points to healthcare and biotech as an alternative for potential growth. In the interview (In Swedish), Ulrica and Mårten Steen (Health Cap) focus on a good end to the summer for American health blocbusters where Astra Zeneca in particular stands out with a breakthrough in diabetes.
Wednesday morning our CIO of Arctic Aurora LifeScience, Ulrica Slåne Bjerke, attended Börslunch at EFN. She discussed the Health Care sector in the present economic conditions, as well as the future prospects of the sector with focus on innovation and a more portfolio approach among the larger companies.
Ulrica Slåne Bjerke has been part of the investment community for more than 15 years as Portfolio Manager in the Health Care sector, and uses her experience and expertise to manage the Arctic Aurora LifeScience fund.
- Read more about Arctic Aurora LifeScience
- Invest in Arctic Aurora LifeScience - Private clients Aksjesparekonto & IPS
- For institutional clients, please contact our Business development team at Arctic Fund Managment
Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. The fund is run by former portfolio manager in the Swedish Governmental Pension Fund AP3, Ulrica Bjerke, as well as Dr. Torbjørn Bjerke, both with 20 years of experience from the market. Arctic Aurora LifeScience was launched in May 2016 with both hedged and un-hedged share classes.
Past performance in Arctic Aurora LifeScience is no guarantee for future returns. Future returns depend on the market, fund manager skill, fund risk level, costs, among others. Performance in the fund may at times be negative and may for this fund vary considerably within periods.